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Effectiveness of Thrombophilia Testing – Testing To A Fault?
Jessica Zimmerberg-Helms MS II, Taylor Goot MD, Allison Burnett Pharm D, Patrick
Rendon MD
University of New Mexico School of Medicine
Department of Internal Medicine

BACKGROUND

METHODS

RESULTS

• Thrombophilias can occur due to a variety of inherited
abnormalities within the coagulation pathway.

•

Out of the 45 patients analyzed, 35% of the charts surveyed

• The question then remains, in the event of a VTE, when is testing
indicated for an inherited or acquired abnormality?
• The standard reasons to consider ordering a hypercoagulability panel:
a) Look for an underlying cause for an unprovoked VTE
b) Assess the probability of a repeat event thereby guiding duration
of anticoagulation therapy
c) Identify asymptomatic family members with an underlying
predisposition to thrombophilia who might benefit from
thromboprophylaxis
The hypercoagulable panel, an order set (HCPAN) consisting of 8 tests
indicated for testing of thrombophilias, was designed to increase testing
efficiency at the University of New Mexico Hospital via collection of
the most commonly ordered tests in one location. However, we
hypothesize that the HCPAN is being ordered outside of guidelinedirected diagnostic utility.

•

A list of 600 HCPAN tests from October 2012 to November 2013 was generated from
the TriCore historical database.
Data included all inpatient and outpatient instances for Internal Medicine patients 18
years and older.

•

•

Following the list generation, the investigators conducted manual chart review of each
patient:
• Charts reviewed evaluated risk factors for VTE, rationale for ordering the HCPAN,
and the service of the ordering provider.
The protocol was approved by the Institutional Review Board for the UNM School of
Medicine.
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Figure 2: Patients with and without active anticoagulation at the
time HCPAN was obtained

Figure 3: HCPAN tests ordered in the presence of an active
thrombus, invalidating some results of the test

Consider testing with
expert interpretation

To examine the HCPAN tests ordered during one year to
determine whether clinicians are ordering the full panels in
accordance with published guidelines and to understand
reasons for ordering the HCPAN in various clinical contexts.

of an active thrombus.

CONCLUSIONS

1) As seen in Figure 1, the majority of HCPANs ordered with
clear documentation were in the setting of a provoked
VTE. These tests were ordered despite guidelines
indicating the test for unprovoked cases only.
2) As seen in Figure 2, a majority of HCPANs are being
drawn from patients with active anticoagulation. Many
components of the HCPAN are invalidated by active
anticoagulation, rendering the results of limited clinical
utility.
3) As seen in Figure 3, a vast majority of HCPANs are drawn
from patients who have an active thrombus. As is the case
with anticoagulation, an active thrombus also invalidates
portions of the HCPAN.
This is evidence that the majority of testing occurs outside of
current guidelines, and establishes that hypercoagulability
testing is an area which would benefit from a quality
improvement intervention.
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patient was actively anticoagulated with one or more of the

The data indicates that the majority of HCPAN tests are being
ordered outside of recommended guidelines and clinical
reasoning for the following reasons:

CONFIRMED VTE

UNPROVOKED
No clear cause for VTE

provoked. 51% of the HCPANs were drawn while the
pharmacologic anticoagulants such as Heparin, Coumadin, or

Figure 1: Charts reviewed which indicated thrombophilia testing in the setting of provoked and
unprovoked VTE
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ordered the HCPN for a VTE that was clearly documented as

Current
Anticoagulation
51%

Not Active
29%

Active Thrombus
60%

REFERENCES
1.Armstrong EM, Bellone JM, Hornsby LB, et al. AcquiredThrombophilia. Journal of Pharmacy
Practice published online 17 April 2014, DOI: 10.1177/0897190014530424.
2.Baglin T, Gray E, Greaves M, et al. Clinical Guidelines for Testing for
Heritable Thrombophilia. Brit J Haematol. 2010;149(2):209-20.
3.De Stefano V and Rossi E. Testing for InheritedThrombophilia and Consequences for
Antithrombotic Prophylaxis in Patients with Venous Thromboembolism and Their
Relatives. Thromb Haemost. 2013;110(4):697

